Trial purpose
Cancer treatment
Tumor type
Haematological
Age
18+
Clinical summary
Summary
This is a Phase 1 open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. This study investigates the following: The safety and tolerability of IMG-7289 The pharmacokinetics of IMG-7289 The pharmacodynamic effect of IMG-7289
Conditions
This trial is treating people with Myelofibrosis
Eligibility
Inclusion
- >18 years of age
- Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, or PPV-MF or PET-MF per the International Working Group for Myelofibrosis Research and Treatment
- High or intermediate-2 risk disease
Exclusion
- Receiving other treatments for the condition (with exceptions and time limits)
- Major surgery in last 4 weeks, any surgery in the last 2 weeks
- History of, or scheduled, hematopoietic stem cell transplant within 24 weeks of Screening
- History of splenectomy
- Current use of prohibited medications
- A concurrent second active and nonstable malignancy
- Known human immunodeficiency virus infection or active Hepatitis B or Hepatitis C virus infection
- Other hematologic/biochemistry requirements, as per protocol
- Use of an investigational agent within last 14 days
- Pregnant or lactating females
Inclusion
- You are able to swallow medication by mouth.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
- You are currently being treated on a clinical trial.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Imago BioSciences,Inc.
Scientific Title
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information